What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

1. Pfizer halts danuglipron development due to potential liver injury in trials. 2. Eli Lilly and Novo Nordisk maintain strong positions in weight-loss market. 3. Viking Therapeutics develops VK2735 for metabolic disorders, reporting data in 2025. 4. Structure Therapeutics reveals positive obesity data for GSBR-1290 in Phase 2a study. 5. GPCR stock rose 8.36% amid positive weight-loss market trends.